SEI Investments
TRIL

SEI Investments’s Trillium Therapeutics Inc. TRIL Stock Holding History

SEI Investments’s Portfolio TRIL Stock Details TRIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-500
Closed -$7K – 3095
2016
Q3 		$7K Hold
500
– – ﹤0.01% 2472
2016
Q2 		$4K Hold
500
– – ﹤0.01% 2425
2016
Q1 		$5K Buy
+500
New +$4.22K ﹤0.01% 2289

Other funds holding TRIL

JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
IBT
International Biotechnology Trust London, United Kingdom $297M AUM 17.25% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

SEI Investments's TRIL Position: Q4 2016 in Review

SEI Investments sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2016, closing a stake of 500 shares — an estimated $7K sold.

SEI Investments first reported a position in TRIL in Q1 2016 and held it in 3 quarters. The position peaked at $7K in Q3 2016. 29 funds tracked by Wall St. Rank hold TRIL as of Q4 2016.

  • SEI Investments reported no remaining Trillium Therapeutics Inc. position as of Q4 2016 after selling out during the quarter.
  • SEI Investments sold 500 Trillium Therapeutics Inc. shares in Q4 2016, an estimated $7K.
  • SEI Investments first reported a position in Trillium Therapeutics Inc. in Q1 2016 and held it in 3 quarters.
  • SEI Investments's Trillium Therapeutics Inc. position peaked at $7K in Q3 2016.
  • 29 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2016.

Based on SEI Investments's 13F filing for Q4 2016, filed 2 Feb 2017.